Literature DB >> 30020504

N-acetylcysteine (NAC) in COPD: benefits often lost in trials.

S Moitra1.   

Abstract

Entities:  

Year:  2019        PMID： 30020504     DOI： 10.1093/qjmed/hcy166

Source DB:  PubMed          Journal:  QJM        ISSN： 1460-2393


× No keyword cloud information.
  5 in total

1.  Efficacy and Safety of Ganduqing Granules in Treating the Common Cold: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Yilan Wang; Piao Zhou; Yuxiao Wu; Huaqin Cao; Wenfeng Hao; Fei Wang; Jing Guo
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-09       Impact factor: 2.650

Review 2.  Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.

Authors:  You Xu; Aneesh Thakur; Yibang Zhang; Camilla Foged
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

Review 3.  Evaluation of Naringenin as a Promising Treatment Option for COPD Based on Literature Review and Network Pharmacology.

Authors:  Zhen Chen; Pan Chen; Hao Wu; Rui Shi; Weiwei Su; Yonggang Wang; Peibo Li
Journal:  Biomolecules       Date:  2020-12-08

Review 4.  Progress in the mechanism and targeted drug therapy for COPD.

Authors:  Cuixue Wang; Jiedong Zhou; Jinquan Wang; Shujing Li; Atsushi Fukunaga; Junji Yodoi; Hai Tian
Journal:  Signal Transduct Target Ther       Date:  2020-10-27

5.  N-Acetylcysteine Improves Inflammatory Response in COPD Patients by Regulating Th17/Treg Balance through Hypoxia Inducible Factor-1α Pathway.

Authors:  Xiaopeng Liu; Zhixiong Hu; Haiying Zhou
Journal:  Biomed Res Int       Date:  2021-06-29       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.